Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:

P611

Baseline faecal MMP-9 level correlates to endoscopic sub-score and post-treatment level correlates to mucosal healing in moderate-to-severe ulcerative colitis patients

Authors:

B. Feagan1, B. Levesque1, J. Woo*2, G. Chen3, H. Wang3, Y. Xiao3, E. Huntzicker2, D. French2, V. Smith4, S. D. Patterson2, M. Subramanian5, B. Kanwar5, W. Sandborn6, B.R. Bhandari7

1Robarts Clinical Trials, London, Ontario, Canada, 2Gilead Sciences, Biomarker, Foster City, California, United States, 3Gilead Sciences, Biostatistics, Foster City, California, United States, 4Gilead Sciences, Biologics and Target Biology, Foster City, California, United States, 5Gilead Sciences, Liver Disease Therapeutic Area, Foster City, California, United States, 6University of California San Diego, Gastroenterology, San Diego, California, United States, 7Gastroenterology and Nutritional Medical Services, Bastrop, Louisiana, United States

P612

Presence and severity of ulcerations in Crohn’s disease does not contribute to response for induction therapy with infliximab in children

Authors:

M. Dadalski*1, A. Wegner2, E. Szymanska3, J. Kierkus1

1Children’s Memorial Health Institute, Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland, 2The Children’s Memorial Health Institute, Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland, 3The Children’s Memorial Health Institute, Paediatrics, Warsaw, Poland

P613

Regulators of glucocorticoid metabolism in inflammatory dowel disease and predicting response to steroid therapy

Authors:

M. Hussey*1, A. Cannon2, G. Holleran1, J. O’Sullivan3, M. Sherlock4, D. McNamara1

1Adelaide and Meath Hospital, Trinity College Dublin, Gastroenterology, Trinity Academic Gastroenterology Group, Dublin, Ireland, 2St James’s Hospital, Trinity College Dublin, Surgery, Dublin, Ireland, 3St James’s Hospital, Trinity College Dublin, Gastroenterology, Dublin, Ireland, 4Adelaide & Meath Hospital, Dublin, Incorporating The National Children’s Hospital, Endocrinology, Dublin, Ireland

P614

Real-world use of adalimumab in UK patients with ulcerative colitis: an observational retrospective study

Authors:

G. Watts1, R. Arasaradnam*2, S. Travis3, A. Sharma4, A. Awasthi5, J. Limdi6, T. Finney-Hayward7

1Wythenshaw Hospital, Manchester, United Kingdom, 2University Hospital Coventry, Coventry, United Kingdom, 3John Radcliffe Hospital, Oxford, United Kingdom, 4Royal Preston Hospital, Preston, United Kingdom, 5Manor Hospital, Walsall, United Kingdom, 6Fairfield General Hospital, Bury, United Kingdom, 7AbbVie Ltd, Maidenhead, United Kingdom

P615

Efficacy and safety of granulocyte, monocyte/macrophage adsorptive apheresis in steroid-dependent active ulcerative colitis with insufficient response or intolerance to immunosuppressants and/or biological therapies (the ART trial): final results

Authors:

A. Dignass*1, A. Akbar2, B. Bonaz3

1Agaplesion Markus Hospital, Department of Medicine I, Frankfurt, Germany, 2St Mark’s Hospital, Gastroenterology, London, United Kingdom, 3CHU de Grenoble, Clinique Universitaire d’Hépato-­Gastroentérologie, Grenoble, France

P616

Early infliximab drug levels predict perianal fistula response to treatment

Authors:

Y. Davidov1, B. Ungar1, O. Haj Natour1, M. Yavzori1, Y. Chowers2, R. Eliakim3, S. Ben-Horin3, U. Kopylov*1

1Sheba Medical Centre, Gastroenterology, Tel Hashomer, Israel, 2Rambam Health Care Campus, Haifa, Israel; Bruce & Ruth Rappaport School of Medicine, Technion Israel Institute of Technology,, Gastroenterology, Haifa, Israel, 3Chaim Sheba Medical Centre, Gastroenterology, Ramat Gan, Israel

P617

Immunogenicity after switching from reference infliximab to biosimilar in children with Crohn’s disease

Authors:

J. Sieczkowska*, D. Jarzebicka, G. Oracz, M. Meglicka, M. Dadalski, J. Kierkus

The Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland

P618

A Mayo endoscopic sub-score of zero predicts long-term remission in patients with ulcerative colitis treated with mesalazine

Authors:

R. Sakemi*1, 2, H. Tanaka1, M. Miyakawa1, M. Nasuno1, S. Motoya1

1Sapporo Kosei General Hospital, IBD Centre, Sapporo, Japan, 2Tobatakyoritsu Hospital, Department of Gastroenterology, Kitakyusyu, Japan

P619

Routine assessment of inflammatory bowel diseases clinical presentations: a prerequisite to check for treatment recommendations

Authors:

M. Timmer1, F. Froehlich2, P. Michetti3, M. H. Maillard4, A. Schoepfer4, C. Mottet5, B. Burnand1, V. Pittet*1

1Institute of Social and Preventive Medicine, Healthcare Evaluation Unit, Lausanne, Switzerland, 2University Hospital Basel, Division of Gastroenterology & Hepatology, Basel, Switzerland, 3Clinique La Source-Beaulieu, Crohn and Colitis Centre, Lausanne, Switzerland, 4Lausanne University Hospital, Department of Gastroenterology & Hepatology, Lausanne, Switzerland, 5Hôpital Neuchâtelois, Service of Gastroenterology, Neuchâtel, Switzerland

P620

Assessment of predictors of the need for biologic therapy in patients with inflammatory bowel disease: a single tertiary centre experience

Authors:

S. Raimundo Fernandes*, L. Correia, P. Moura Santos, A. Rita Gonçalves, A. Valente, C. Baldaia, J. Velosa

Centro Hospitalar Lisboa Norte, Gastrenterology, Lisbon, Portugal

P621

Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel diseases (IBD): Interim results of the TEDDY study

Authors:

M. Chaparro1, F. Magro2; E. Savarino3, Y. Zabana4, D. Pugliese5, A. Bar-Gil Shitrit6, L. Fernandes Samue7, P. López-Serrano8, M. J. Casanova1, L. Fernández-Salazar9, A. Gutierrez10, R. Vicente11, E. Gravito-Soares12, C. Rodriguez13, L. Sebkova14, D. Lissner15, A. Magarotto16, I. Rodriguez-Lago17, J. M. Huguet18, M. T. Diz-Lois Palomares19, G. Fiorino20, I. Guerra21, G. J. Mantzaris22, M. Silva2, O. Bartolo3, M. G. Donday1, M. Ramas1, J. Martín de Carpi23, J. P. Gisbert1

Gastroenterology Departments from: 1Hospital Universitario de la Princesa, IIS-IP y CIBEREHD, Madrid, Spain; 2Centro Hospitalar Sao Joao, Portugal; 3University of Padua, Italy; 4Hospital Universitari Mutua de Terrassa, Terrassa, Spain; 5Complesso Integrato Columbus Catholic University, Italy; 7Shaare Zedek Medical Center Jerusalem, Israel; 7Hospital de Santa Maria de Lisboa, Portugal; 8Hospital Universitario Fundación de Alcorcón, Spain; 9Hospital Clínico Universitario de Valadolid, Spain; 10Hospital General de Alicante, Spain; 11Hospital Universitario Miguel Servet, Spain; 12Centro Hospitalar e Universitario de Coimbra, Portugal; 13Complejo hospitalario de Navarra, Spain; 14Azienda Ospedaliera “Plugiese-Ciaccio”, Italy; 15Universitatsmedizin Berlin, Campus Benjamin Franklin, Charite, Germany; 16IRCCS Ospedale Ca Granda Policlinico di Milano, Italy; 17Hospital Galdakao, Spain; 18Hospital General Universitario de Valencia, Spain; 19Hospital Universitario A Coruña, Spain; 20Humanitas Research Hospital, Italy; 21Hospital Universitario de Fuenlabrada, Spain; 22Evangelismos, Ophthalmiatreion Athinon and Polyclinic Hospitals, Greece; 23Unidad para el Cuidado Integral de la Enfermedad Inflamatoria Intestinal. Hospital Sant Joan de Déu, Barcelona.

P622

In a Dutch real-life inflammatory bowel disease score cohort with 90% prior anti-tumour necrosis factor failure, vedolizumab showed a 25% remission rate: a retrospective multicentre study

Authors:

R. Y. Gabriëls*1, A. P. J. de Graaf2, M. A. C. Meijssen2, J. M. Götz3, P. B. Mensink3, M. G. V. M. Russel3, H. M. Dullemen1, R. W. F. ter Steege1, R. K. Weersma1, G. Dijkstra1

1University of Groningen, University Medical Centre Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, 2Isala Hospital Sophia, Department of Gastroenterology and Hepatology, Zwolle, Netherlands, 3Medical Spectrum Twente, Department of Gastroenterology and Hepatology, Enschede, Netherlands

P623

Once versus twice daily mesalazine to induce remission in paediatric ulcerative colitis: an investigator-initiated randomised controlled trial

Authors:

D. Turner*1, B. Yerushalmi2, M. Kori3, E. Broide4, Y. Mozer-Glassberg5, R. Shaoul6, K.-L. Kolho7, E. Shteyer8, H. Shamaly9, O. Ledder10, S. Cohen11, S. Peleg12, A. On13, A. Levine14

1Shaare Zedek Medical Centre, Institute of Paediatric Gastroenterology, Jerusalem, Israel, 2Soroka Medical Centre, Beer Sheva, Israel, 3Kaplan Hospital, Rehovot, Israel, 4Asaff Harofeh, Tel Aviv, Israel, 5Schneider’s Children Hospital, Petach Tikva, Israel, 6Rambam medical Centre, Haifa, Israel, 7Children´s Hospital, University of Helsinki, Helsinki, Finland, 8Hadassah Medical Centre, Jerusalem, Israel, 9French Hospital, Nazareth, Israel, 10Shaare Zedek Medical Centre, Jerusalem, Israel, 11Tel Aviv Medical Centre, Tel Aviv, Israel, 12Emek Medical Centre, Afula, Israel, 13Poria, Tiberias, Israel, 14Wolfson Medical Centre, Holon, Israel

P624

Effectiveness and safety of vedolizumab for the induction of remission in inflammatory bowel disease

Authors:

M. Chaparro*1, M. Sierra-Ausin2, F. Mesonero3, N. Maroto4, C. Fernandez de Castro5, V. García-Sánchez6, A.J. Lucendo7, D. Busquets8, M. Barreiro-de Acosta9, I. Marín-Jiménez10, B. Beltrán11, L. Ruiz Belmonte12, F. Bermejo13, M. Mínguez14, R. Pajares15, J. R. Pineda16, B. Sicilia17, D. Martín-Rodríguez18, A. Gutiérrez19, S. Rubio20, I. García Tercero21, M. Piqueras22, D. Ginard23, B. Jucha24, C. Muñoz Villafranca25, M. D. Martín-Arranz26, L. Marti Romero27, E. M. Fernández Bonilla28, A. Echarri29, J. F. Forcelledo30, M. G. Donday1, M. Ramas1, J. P. Gisbert1

1Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain, 2Hospital Universitario de León, Gastroenterology Unit, León, Spain, 3Hospital Universitario Ramón y Cajal, Gastroenterology Unit, Madrid, Spain, 4Hospital de Manises, Gastroenterology Unit, Valencia, Spain, 5Hospital Universitario Central de Asturias, Gastroenterology Unit, Oviedo, Spain, 6Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain, 7Hospital General de Tomelloso, Gastroenterology Unit, Tomelloso, Spain, 8Hospital universitari de Girona Dr Josep Trueta, Gastroenterology Unit, Girona, Spain, 9Hospital Clínico Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 10Hospital Gregorio Marañón and IiSGM, Gastroenterology Unit, Madrid, Spain, 11Hospital Universitario La Fe and CIBERehd, Gastroenterology Unit, Valencia, Spain, 12Hospital Universitario Miguel Servet, Gastroenterology Unit, Zaragoza, Spain, 13Hospital Universitario de Fuenlabrada, Gastroenterology Unit, Madrid, Spain, 14Hospital Clínico Universitario de Valencia, Gastroenterology Unit, Valencia, Spain, 15Hospital Infanta Sofía, Gastroenterology Unit, Madrid, Spain, 16Hospital Álvaro Cunqueiro, Gastroenterology Unit, Vigo, Spain, 17Hospital Universitario de Burgos, Gastroenterology unit, Burgos, Spain, 18Hospital Universitario Infanta Cristina, Gastroenterology Unit, Madrid, Spain, 19Hospital General Universitario de Alicante and CIBERehd, Gastroenterology Unit, Alicante, Spain, 20Complejo Hospitalario de Navarra, Gastroenterology Unit, Pamplona, Spain, 21Hospital Universitario Santa Lucía, Gastroenterology Unit, Cartagena, Spain, 22Consorcio Sanitario de Terrassa, Gastroenterology Unit, Barcelona, Spain, 23Hospital Universitario Son Espases, Gastroenterology Unit, Palma de Mallorca, Spain, 24Hospital Comarcal de Melilla, Gastroenterology Unit, Melilla, Spain, 25Hospital de Basurto, Gastroenterology Unit, Bilbao, Spain, 26Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain, 27Hospital Francisco de Borja, Gastroenterology Unit, Gandía, Spain, 28Hospital de Alcañiz, Gastroenterology Unit, Teruel, Spain, 29Complejo Hospitalario Universitario de Ferrol, Gastroenterology Unit, Coruña, Spain, 30Hospital Sierrallana, Gastroenterology Unit, Torrelavega, Spain

P625

Frequency and clinical factors associated with histologic remission in patients with ulcerative colitis: a retrospective cohort study in a Latin American country

Authors:

J. Yamamoto-Furusho*1, G. Sanchez-Morales2

1IBD Clinic, Instituto Nacional de Ciencias Medicas y Nutricion, Gastroenterology, Mexico, Mexico, 2Instituto Nacional de Ciencias Medicas y Nutricion, Gastroenterology, Mexico, Mexico

P626

Prevalence of inflammatory bowel disease amongst patients with psoriasis and incidence of serious infections in this subset: results from the PSOLAR Registry

Authors:

E. Loftus, Jr1, M. Augustin2, R. Bissonnette3, G. Krueger4, S. Calabro5, W. Langholff6, J. Popp7, K. Goyal5, S. Sloan*8

1Mayo Clinic Rochester, Department of Gastroenterology, Rochester, Minnesota, United States, 2University Clinics of Hamburg, Hamburg, Germany, 3Innovaderm Research, Inc, Montreal, Canada, 4University of Utah, Salt Lake City, Utah, United States, 5Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, United States, 6Janssen R & D, LLC, Horsham, Pennsylvania, United States, 7Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, United States, 8Janssen Global Services, Horsham, Pennsylvania, United States

P627

What is the need for, and acceptability of, routine, integrated psychological care in an established inflammatory bowel disease (IBD) service? Early data from a new initiative in clinical IBD care

Authors:

T. Lores*1, C. Goess1, R. Grafton1, J. Hughes1, L. Cronin1, A. Mikocka-Walus2, A. Chur-Hansen3, A. Burke4, K. Collins4, J. Andrews1

1Royal Adelaide Hospital, Gastroenterology, Adelaide, Australia, 2University of York, Heslington, United Kingdom, 3University of Adelaide, Adelaide, Australia, 4Royal Adelaide Hospital, Psychology, Adelaide, Australia

P628

Patient-reported adherence rates to topical therapies in ulcerative colitis

Authors:

P. Hendy*1, 2, M. Shuvo3, A. Hart1

1St Mark’s Hospital, Gastroenterology, LONDON, United Kingdom, 2Imperial College, Antigen Presentation Research Group, London, United Kingdom, 3Royal Liverpool University Teaching Hospital, Department of Gastroenterology, 5Z Link Unit, Liverpool, United Kingdom

P629

Improvement of nutritional status and growth velocity as an additional benefit from using the exclusive enteral nutrition to induce remission in children with active Crohn’s disease

Authors:

M. Matuszczyk*1, M. Meglicka1, P. Landowski2, B. Sordyl3, E. Czkwaniec3, J. Kierkuś1

1The Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland, 2Medical University of Gdańsk, Gdańsk, Poland, 3Polish Mother’s Memorial Hospital Research Institute, Łódź, Poland

P630

Screening for latent and previous infectious diseases in inflammatory bowel disease patients: Is it a must for correct treatment decisions?

Authors:

M. Ardesia*1, S. Maisano1, G. Costantino1, A. Alibrandi2, W. Fries1

1University of Messina, Department of Clinical and Experimental Medicine, Messina, Italy, 2University of Messina, Department of Economical, Financial, Social, Environmental, Statistical and Territorial Sciences, Messina, Italy